Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

28.53 -0.51 (-1.76%)
Streaming Delayed Price Updated: 2:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum ↗
Discover ARQT stock, a top growth pick blending Minervini's strong trend template with explosive earnings and sales momentum for potential outperformance. 
Via Chartmill
News headline image
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Top 5 Biotech Stocks With Strong Momentum ↗
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies. 
Via Benzinga
News headline image
3 Biotech Catalysts Present Major Opportunity ↗
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum ↗
Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors. 
Via Chartmill
News headline image
Arcutis (ARQT) Q2 Revenue Soars 164% ↗
Via The Motley Fool
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected ↗
Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings. 
Via Chartmill
News headline image
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis ↗
Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema. 
Via Benzinga
News headline image
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Arcutis Biotherapeutics's Future ↗
 
Via Benzinga
News headline image
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick? ↗
A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing? 
Via Chartmill
News headline image
Arcutis Announces Chief Financial Officer Transition
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews ↗
 
Via Benzinga
News headline image
Arcutis and Padagis Agree to Stay Patent Lawsuit
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move ↗
A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500. 
Via Talk Markets
Topics Stocks Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.